{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:24:32Z","timestamp":1775003072749,"version":"3.50.1"},"publisher-location":"Cham","reference-count":87,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783032041524","type":"print"},{"value":"9783032041531","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-3-032-04153-1_13","type":"book-chapter","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T23:30:14Z","timestamp":1774999814000},"page":"207-219","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lysosomal Neuraminidase 1 (NEU1): Its Unique Molecular Characters and Therapeutic Approaches for Deficiencies"],"prefix":"10.1007","author":[{"given":"Kohji","family":"Itoh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Tsukimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"13_CR1","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/j.cellsig.2014.02.015","volume":"26","author":"F Alghamdi","year":"2014","unstructured":"Alghamdi F, Guo M, Abdulkhalek S, Crawford N, Amith SR, Szewczuk MR (2014) A novel insulin receptor-signaling platform and its link to insulin resistance and type 2 diabetes. Cell Signal 26:1355\u20131368. https:\/\/doi.org\/10.1016\/j.cellsig.2014.02.015","journal-title":"Cell Signal"},{"key":"13_CR2","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1038\/ncomms3734","volume":"4","author":"I Annunziata","year":"2013","unstructured":"Annunziata I et al (2013) Lysosomal NEU1 deficiency affects amyloid precursor protein levels and amyloid-\u03b2 secretion via deregulated lysosomal exocytosis. Nat Commun 4:2734. https:\/\/doi.org\/10.1038\/ncomms3734","journal-title":"Nat Commun"},{"key":"13_CR3","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","volume":"1324","author":"NW Barton","year":"1991","unstructured":"Barton NW et al (1991) Replacement therapy for inherited enzyme deficiency\u2013macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease. N Engl J Med 1324:1464\u20131470. https:\/\/doi.org\/10.1056\/NEJM199105233242104","journal-title":"N Engl J Med"},{"key":"13_CR5","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1101\/gad.10.24.3156","volume":"10","author":"EJ Bonten","year":"1996","unstructured":"Bonten EJ, van Der Spoel A, Fornerod M, Grosveld G, d\u2019Azzo A (1996) Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder Sialidosis. Genes Dev 10:3156\u20133169","journal-title":"Genes Dev"},{"key":"13_CR6","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1096\/fj.03-0941fje","volume":"18","author":"EJ Bonten","year":"2004","unstructured":"Bonten EJ, Wang D, Toy JN, Mann L, Mignardot A, Yogalingam G, d\u2019Azzo A (2004) Targeting macrophages with baculovirus-produced lysosomal enzymes: implications for enzyme replacement therapy of the glycoprotein storage disorder galactosialidosis. FASEB J 18:971\u2013973. https:\/\/doi.org\/10.1096\/fj.03-0941fje","journal-title":"FASEB J"},{"key":"13_CR7","doi-asserted-by":"publisher","first-page":"28430","DOI":"10.1074\/jbc.M109.031419","volume":"284","author":"EJ Bonten","year":"2009","unstructured":"Bonten EJ et al (2009) Heterodimerization of the sialidase NEU1 with the chaperone protective protein\/cathepsin A prevents its premature oligomerization. J Biol Chem 284:28430\u201328441. https:\/\/doi.org\/10.1074\/jbc.M109.031419","journal-title":"J Biol Chem"},{"key":"13_CR8","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.bbadis.2013.06.002","volume":"1832","author":"EJ Bonten","year":"2013","unstructured":"Bonten EJ, Yogalingam G, Hu H, Gomero E, van de Vlekkert D, d'Azzo A (2013) Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis. Biochim Biophys Acta 1832:1784\u20131792. https:\/\/doi.org\/10.1016\/j.bbadis.2013.06.002","journal-title":"Biochim Biophys Acta"},{"key":"13_CR9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/1750-1172-8-114","volume":"8","author":"A Caciotti","year":"2013","unstructured":"Caciotti A (2013) Galactosialidosis: review and analysis of CTSA gene mutations. Orphanet J Rare Dis 8:114. https:\/\/doi.org\/10.1186\/1750-1172-8-114","journal-title":"Orphanet J Rare Dis"},{"key":"13_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ymgme.2019.09.005","volume":"129","author":"A Caciotti","year":"2020","unstructured":"Caciotti A et al (2020) Type I sialidosis, a normosomatic lysosomal disease, in the differential diagnosis of late-onset ataxia and myoclonus: an overview. Mol Genet Metab 129:47\u201358. https:\/\/doi.org\/10.1016\/j.ymgme.2019.09.005","journal-title":"Mol Genet Metab"},{"key":"13_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.omtm.2020.11.012","volume":"20","author":"J Cadaoas","year":"2021","unstructured":"Cadaoas J et al (2021) Galactosialidosis: preclinical enzyme replacement therapy in a mouse model of the disease, a proof of concept. Mol Ther Methods Clin Dev 20:191\u2013203. https:\/\/doi.org\/10.1016\/j.omtm.2020.11.012","journal-title":"Mol Ther Methods Clin Dev"},{"key":"13_CR12","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/glycob\/7.7.975","volume":"7","author":"MB Carrillo","year":"1997","unstructured":"Carrillo MB, Milner CM, Ball ST, Snoek M, Campbell RD (1997) Cloning and characterization of a sialidase from the murine histocompatibility-2 complex: low levels of mRNA and a single amino acid mutation are responsible for reduced sialidase activity in mice carrying the Neu1a allele. Glycobiology 7:975\u2013986. https:\/\/doi.org\/10.1093\/glycob\/7.7.975","journal-title":"Glycobiology"},{"key":"13_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1074\/jbc.M411506200","volume":"280","author":"LMG Chavas","year":"2005","unstructured":"Chavas LMG et al (2005) Crystal structure of the human cytosolic sialidase Neu2. Evidence for the dynamic nature of substrate recognition. J Biol Chem 280:469\u2013475. https:\/\/doi.org\/10.1074\/jbc.M411506200","journal-title":"J Biol Chem"},{"key":"13_CR14","doi-asserted-by":"publisher","first-page":"4535","DOI":"10.1073\/pnas.79.15.4535","volume":"79","author":"A d\u2019Azzo","year":"1982","unstructured":"d\u2019Azzo A, Hoogeveen A, Reuser AJ, Robinson D, Galjaard H (1982) Molecular defect in combined beta-galactosidase and neuraminidase deficiency in man. Proc Natl Acad Sci USA 79:4535\u20134539. https:\/\/doi.org\/10.1073\/pnas.79.15.4535","journal-title":"Proc Natl Acad Sci USA"},{"key":"13_CR15","first-page":"3811","volume-title":"The metabolic and molecular bases of inherited disease","author":"A d\u2019Azzo","year":"2001","unstructured":"d\u2019Azzo A, Andria G, Strisciuglio P, Galjaard H (2001) Galactosialidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, vol 3, 8th edn. McGraw-Hill, pp 3811\u20133826","edition":"8"},{"key":"13_CR16","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1093\/hmg\/11.12.1455","volume":"11","author":"N de Geest","year":"2007","unstructured":"de Geest N, Bonten E, Mann L, de Sousa-Hitzler J, Hahn C, d\u2019Azzo A (2007) Systemic and neurologic abnormalities distinguish the lysosomal disorders sialidosis and galactosialidosis in mice. Hum Mol Genet 11:1455\u20131464. https:\/\/doi.org\/10.1093\/hmg\/11.12.1455","journal-title":"Hum Mol Genet"},{"key":"13_CR17","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018756","volume":"10","author":"EP Demina","year":"2021","unstructured":"Demina EP et al (2021) Neuraminidases 1 and 3 trigger atherosclerosis by desialylating low-density lipoproteins and increasing their uptake by macrophages. J Am Heart Assoc 10:e018756. https:\/\/doi.org\/10.1161\/JAHA.120.018756","journal-title":"J Am Heart Assoc"},{"key":"13_CR18","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.2337\/db12-1825","volume":"62","author":"L Dridi","year":"2013","unstructured":"Dridi L et al (2013) Positive regulation of insulin signaling by neuraminidase 1. Diabetes 62:2338\u20132346. https:\/\/doi.org\/10.2337\/db12-1825","journal-title":"Diabetes"},{"key":"13_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41591-021-01664-4","volume":"28","author":"TR Flotte","year":"2022","unstructured":"Flotte TR et al (2022) AAV gene therapy for Tay-Sachs disease. Nat Med 28:251\u2013259. https:\/\/doi.org\/10.1038\/s41591-021-01664-4","journal-title":"Nat Med"},{"key":"13_CR20","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/s0092-8674(88)90999-3","volume":"54","author":"NJ Galjart","year":"1988","unstructured":"Galjart NJ, Gillemans N, Harris A, van der Horst GTJ, Verheijen FW, Galjaard H, d\u2019Azzo A (1988) Expression of CDNA encoding the human \u201cProtective Protein\u201d associated with lysosomal \u03b2-galactosidase and neuraminidase: homology to yeast proteases. Cell 54:755\u2013764. https:\/\/doi.org\/10.1016\/s0092-8674(88)90999-3","journal-title":"Cell"},{"key":"13_CR1000","doi-asserted-by":"publisher","unstructured":"Gallat F-X, Matsugaki N, Coussens NP, Yagi KJ, Boudes M, Higashi T, Tsuji D, Tatano Y, Suzuki M, Mizohata E, Tono K, Joti Y, Kameshima T, Park J, Song C, Hatsui T, Yabashi M, Nango E, Itoh K, Coulibaly F, Tobe S, Ramaswamy S, Stay B, Iwata S, Chavas LMG (2014) In vivo crystallography at x-ray free-electron lasers: the next generation of structural biology? Philos Trans R Soc B 369:20130497\u201320130497. https:\/\/doi.org\/10.1098\/rstb.2013.0497","DOI":"10.1098\/rstb.2013.0497"},{"key":"13_CR21","doi-asserted-by":"publisher","first-page":"4155","DOI":"10.1126\/sciadv.abf4155","volume":"7","author":"A Gorelik","year":"2021","unstructured":"Gorelik A, Illes K, Hasan SMN, Nagar B, Mazhab-Jafari MT (2021) Structure of the Murine lysosomal multienzyme complex core. Sci Adv 7:4155\u20134167. https:\/\/doi.org\/10.1126\/sciadv.abf4155","journal-title":"Sci Adv"},{"key":"13_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ymgme.2014.02.011","volume":"112","author":"GA Grabowski","year":"2014","unstructured":"Grabowski GA, Golembo M, Shaaltiel Y (2014) Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology. Mol Genet Metab 112:1\u20138. https:\/\/doi.org\/10.1016\/j.ymgme.2014.02.011","journal-title":"Mol Genet Metab"},{"key":"13_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.821317","volume":"9","author":"Z Guo","year":"2022","unstructured":"Guo Z et al (2022) NEU1 regulates mitochondrial energy metabolism and oxidative stress post-myocardial infarction in Mice via the SIRT1\/PGC-1 alpha axis. Front Cardiovasc Med 9:821317. https:\/\/doi.org\/10.3389\/fcvm.2022.821317","journal-title":"Front Cardiovasc Med"},{"key":"13_CR24","doi-asserted-by":"publisher","first-page":"14880","DOI":"10.1073\/pnas.95.25.14880","volume":"95","author":"CN Hahn","year":"1998","unstructured":"Hahn CN, del Pilar MM, Zhou XY, Mann LW, d\u2019Azzo A (1998) Correction of murine galactosialidosis by bone marrow-derived macrophages over-expressing human protective protein\/cathepsin A under control of the colony-stimulating factor-1 receptor promoter. Proc Natl Acad Sci USA 95:14880\u201314885. https:\/\/doi.org\/10.1073\/pnas.95.25.14880","journal-title":"Proc Natl Acad Sci USA"},{"key":"13_CR25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s00395-020-00821-z","volume":"115","author":"M Heimerl","year":"2020","unstructured":"Heimerl M, Sieve I, Ricke-Hoch M, Erschow S, Battmer K, Scherr M, Hilfiker-Kleiner D (2020) Neuraminidase-1 promotes heart failure after ischemia\/reperfusion injury by affecting cardiomyocytes and invading monocytes\/macrophages. Basic Res Cardiol 115:62. https:\/\/doi.org\/10.1007\/s00395-020-00821-z","journal-title":"Basic Res Cardiol"},{"key":"13_CR26","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1074\/jbc.M508736200","volume":"281","author":"A Hinek","year":"2006","unstructured":"Hinek A, Pshezhetsky AV, von Itzstein M, Starcher B (2006) Lysosomal sialidase (neuraminidase-1) is targeted to the cell surface in a multiprotein complex that facilitates elastic fiber assembly. J Biol Chem 281:3698\u20133710. https:\/\/doi.org\/10.1074\/jbc.M508736200","journal-title":"J Biol Chem"},{"key":"13_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1273\/cbij.13.30","volume":"13","author":"S Hitaoka","year":"2013","unstructured":"Hitaoka S et al (2013) Modeling of human neuraminidase-1 (NEU1) and its validation by LARE-correlation analysis. Chem-Bio Informatics 13:30\u201344","journal-title":"Chem-Bio Informatics"},{"key":"13_CR28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1021\/acschemneuro.8b00408","volume":"10","author":"RJ Holley","year":"2019","unstructured":"Holley RJ, Wood SR, Bigger BW (2019) Delivering hematopoietic stem cell gene therapy treatments for neurological lysosomal diseases. ACS Chem Neurosci 10:18\u201320. https:\/\/doi.org\/10.1021\/acschemneuro.8b00408","journal-title":"ACS Chem Neurosci"},{"key":"13_CR29","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.omtm.2022.04.001","volume":"25","author":"Y Horii","year":"2020","unstructured":"Horii Y et al (2020) Reversal of neuroinflammation in novel GS model mice by single i.c.v. administration of CHO-derived rhCTSA precursor protein. Mol Ther Methods Clin Dev 25:297\u2013310. https:\/\/doi.org\/10.1016\/j.omtm.2022.04.001","journal-title":"Mol Ther Methods Clin Dev"},{"key":"13_CR30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/mt.2011.227","volume":"20","author":"H Hu","year":"2012","unstructured":"Hu H et al (2012) Preclinical dose-finding study with a liver-tropic, recombinant AAV-2\/8 vector in the mouse model of galactosialidosis. Mol Ther 20:267\u2013274. https:\/\/doi.org\/10.1038\/mt.2011.227","journal-title":"Mol Ther"},{"key":"13_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/hmg\/7.1.115","volume":"7","author":"SA Igdoura","year":"1998","unstructured":"Igdoura SA (1998) Cloning of the cDNA and gene encoding mouse lysosomal sialidase and correction of sialidase deficiency in human sialidosis and mouse SM\/J fibroblasts. Hum Mol Genet 7:115\u2013121. https:\/\/doi.org\/10.1093\/hmg\/7.1.115","journal-title":"Hum Mol Genet"},{"key":"13_CR32","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/S0021-9258(18)54057-6","volume":"268","author":"K Itoh","year":"1993","unstructured":"Itoh K (1993) Purification and characterization of human lysosomal protective protein expressed in stably trans-formed Chinese Hamster ovary cells. J Biol Chem 268:1180\u20131186","journal-title":"J Biol Chem"},{"key":"13_CR33","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s10719-023-10135-6","volume":"40","author":"K Itoh","year":"2023","unstructured":"Itoh K, Tsukimoto J (2023) Lysosomal sialidase NEU1, its intracellular properties, deficiency, and use as a therapeutic agent. Glycoconj J 40:611\u2013619. https:\/\/doi.org\/10.1007\/s10719-023-10135-6","journal-title":"Glycoconj J"},{"key":"13_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/BF01876581","volume":"36","author":"K Itoh","year":"1991","unstructured":"Itoh K, Takiyama N, Nagao Y, Oshima A, Sakuraba H, Potier M, Suzuki Y (1991) Acid carboxypeptidase deficiency in galactosialidosis. Jpn J Hum Genet 36:169\u2013175. https:\/\/doi.org\/10.1007\/BF01876581","journal-title":"Jpn J Hum Genet"},{"key":"13_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10038-002-8652-7","volume":"47","author":"K Itoh","year":"2001","unstructured":"Itoh K et al (2001) Novel missense mutations in the human lysosomal sialidase gene in sialidosis patients and prediction of structural alterations of mutant enzymes. J Hum Genet 47:29\u201337. https:\/\/doi.org\/10.1007\/s10038-002-8652-7","journal-title":"J Hum Genet"},{"issue":"12","key":"13_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.626110","volume":"3","author":"J Karmakar","year":"2021","unstructured":"Karmakar J, Mandal C (2021) Interplay between sialic acids, Siglec-E, and Neu1 regulates MyD88- and TRIF-dependent pathways for TLR4-activation during Leishmania donovani infection. Front Immunol 3(12):626110. https:\/\/doi.org\/10.3389\/fimmu.2021.626110","journal-title":"Front Immunol"},{"key":"13_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.811600","volume":"12","author":"S Katoh","year":"2022","unstructured":"Katoh S (2022) Critical involvement of CD44 in T Helper Type 2 cell-mediated Eosinophilic airway inflammation in a Mouse Model of acute asthma. Front Immunol 12:811600. https:\/\/doi.org\/10.3389\/fimmu.2021.811600","journal-title":"Front Immunol"},{"key":"13_CR38","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1365-2249.2010.04165.x","volume":"161","author":"S Katoh","year":"2010","unstructured":"Katoh S, Maeda S, Fukuoka H, Wada T, Moriya S, Mori A, Yamaguchi K, Senda S, Miyagi T (2010) A crucial role of sialidase Neu1 in hyaluronan receptor function of CD44 in T helper type 2-mediated airway inflammation of murine acute asthmatic model. Clin Exp Immunol 161:233\u2013241. https:\/\/doi.org\/10.1111\/j.1365-2249.2010.04165.x","journal-title":"Clin Exp Immunol"},{"key":"13_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.902259","volume":"13","author":"A Khan","year":"2022","unstructured":"Khan A, Sergi CM (2022) NEU1-A unique therapeutic target for Alzheimer's disease. Front Pharmacol 13:902259. https:\/\/doi.org\/10.3389\/fphar.2022.902259","journal-title":"Front Pharmacol"},{"key":"13_CR40","doi-asserted-by":"publisher","DOI":"10.1177\/1533317521996147","volume":"36","author":"A Khan","year":"2021","unstructured":"Khan A, Das S, Sergi CM (2021) Therapeutic potential of Neu1 in Alzheimer's disease via the immune system. Am J Alzheimers Dis Other Dement 36:1533317521996147. https:\/\/doi.org\/10.1177\/1533317521996147","journal-title":"Am J Alzheimers Dis Other Dement"},{"key":"13_CR41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","volume":"68","author":"PS Kishnani","year":"2007","unstructured":"Kishnani PS et al (2007) Recombinant human acid \u03b1-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68:99\u2013109. https:\/\/doi.org\/10.1212\/01.wnl.0000251268.41188.04","journal-title":"Neurology"},{"key":"13_CR42","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1021\/acsabm.9b00686","volume":"2","author":"K Koiwai","year":"2019","unstructured":"Koiwai K et al (2019) Improvement of production and isolation of human Neuraminidase-1 in Cellulo crystals. ACS Appl Bio Mater 2:4941\u20134952. https:\/\/doi.org\/10.1021\/acsabm.9b00686","journal-title":"ACS Appl Bio Mater"},{"key":"13_CR43","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.bbrc.2012.10.028","volume":"428","author":"K Koseki","year":"2012","unstructured":"Koseki K, Wada T, Hosono M, Hata K, Yamaguchi K, Nitta K, Miyagi T (2012) Human: cytosolic sialidase NEU2-low general tissue expression but involvement in PC-3 prostate cancer cell survival. Biochem Biophys Res Commun 428:142\u2013149. https:\/\/doi.org\/10.1016\/j.bbrc.2012.10.028","journal-title":"Biochem Biophys Res Commun"},{"key":"13_CR44","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.cccn.2004.02.032","volume":"344","author":"M Kotani","year":"2004","unstructured":"Kotani M, Yamada H, Sakuraba H (2004) Cytochemical and biochemical detection of intracellularly accumulated sialyl glycoconjugates in sialidosis and galactosialidosis fibroblasts with Macckia amurensis. Clin Chim Acta 344:131\u2013135. https:\/\/doi.org\/10.1016\/j.cccn.2004.02.032","journal-title":"Clin Chim Acta"},{"key":"13_CR45","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1182\/blood.v99.9.3169","volume":"99","author":"T Leimig","year":"2002","unstructured":"Leimig T et al (2002) Functional amelioration of murine galactosialidosis by genetically modified bone marrow hematopoietic progenitor cells. Blood 99:3169\u20133178. https:\/\/doi.org\/10.1182\/blood.v99.9.3169","journal-title":"Blood"},{"key":"13_CR46","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1399-0004.1984.tb00804.x","volume":"26","author":"MCB Loonen","year":"1984","unstructured":"Loonen MCB, Reuser AJJ, Visser P, Arts WFM (1984) Combined Sialidase (neuraminidase) and \u03b2-galactosidase deficiency. Clinical, morphological and enzymological observations in a patient. Clin Genet 26:139\u2013149. https:\/\/doi.org\/10.1111\/j.1399-0004.1984.tb00804.x","journal-title":"Clin Genet"},{"key":"13_CR47","doi-asserted-by":"publisher","first-page":"46172","DOI":"10.1074\/jbc.M104547200","volume":"276","author":"KE Lukong","year":"2001","unstructured":"Lukong KE (2001) Intracellular distribution of lysosomal Sialidase is controlled by the internalization signal in its cytoplasmic tail. J Biol Chem 276:46172\u201346181. https:\/\/doi.org\/10.1074\/jbc.M104547200","journal-title":"J Biol Chem"},{"key":"13_CR48","doi-asserted-by":"publisher","first-page":"13556","DOI":"10.1074\/jbc.RA119.010794","volume":"295","author":"AR Luu","year":"2020","unstructured":"Luu AR (2020) Intermittent enzyme replacement therapy prevents Neu1 deficiency. J Biol Chem 295:13556\u201313569. https:\/\/doi.org\/10.1074\/jbc.RA119.010794","journal-title":"J Biol Chem"},{"key":"13_CR49","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40265-019-01090-4","volume":"79","author":"EH McCafferty","year":"2019","unstructured":"McCafferty EH, Scott LJ (2019) Migalastat: a review in Fabry disease. Drugs 79:543\u2013554. https:\/\/doi.org\/10.1007\/s40265-019-01090-4","journal-title":"Drugs"},{"key":"13_CR51","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1006\/geno.1999.5749","volume":"57","author":"E Monti","year":"1999","unstructured":"Monti E, Preti A, Rossi E, Ballabio A, Borsani G (1999) Cloning and characterization of NEU2, a human gene homologous to rodent soluble sialidases. Genomics 57:137\u2013143. https:\/\/doi.org\/10.1006\/geno.1999.5749","journal-title":"Genomics"},{"key":"13_CR1001","doi-asserted-by":"publisher","unstructured":"Monti E, Bassi MT, Papini N, Riboni M, Manzoni M, Venerando B, Croci G, Preti A, Ballabio A, Tettamanti G, Borsani G (2000) Identification and expression of NEU3, a novel human sialidase associated to the plasma membrane. Biochem J 1:343\u2013351. https:\/\/doi.org\/10.1042\/0264-6021:3490343","DOI":"10.1042\/0264-6021:3490343"},{"key":"13_CR52","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ygeno.2003.08.019","volume":"83","author":"E Monti","year":"2004","unstructured":"Monti E et al (2004) Molecular cloning and characterization of NEU4, the fourth member of the human sialidase gene family. Genomics 83:445\u2013453. https:\/\/doi.org\/10.1016\/j.ygeno.2003.08.019","journal-title":"Genomics"},{"key":"13_CR53","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0065-2318(10)64007-3","volume-title":"Adv Carbohydr Chem Biochem","author":"E Monti","year":"2010","unstructured":"Monti E et al (2010) Sialidases in vertebrates. A family of enzymes tailored for several cell functions. In: Adv Carbohydr Chem Biochem, vol 64. Academic Press Inc, pp 403\u2013479. https:\/\/doi.org\/10.1016\/S0065-2318(10)64007-3"},{"key":"13_CR54","doi-asserted-by":"publisher","first-page":"17949","DOI":"10.1016\/S0021-9258(19)37135-2","volume":"267","author":"H Morreau","year":"1992","unstructured":"Morreau H, Galjart NJ, Willemsen R, Gillemans N, Zhou XY, d\u2019Azzo A (1992) Human lysosomal protective protein. Glycosylation, intracellular transport, and association with beta-galactosidase in the endoplasmic reticulum. J Biol Chem 267:17949\u201317956","journal-title":"J Biol Chem"},{"key":"13_CR55","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3390\/jcm9030695","volume":"9","author":"R Mosca","year":"2002","unstructured":"Mosca R et al (2002) Conventional and unconventional therapeutic strategies for Sialidosis Type I. J Clin Med 9:695. https:\/\/doi.org\/10.3390\/jcm9030695","journal-title":"J Clin Med"},{"key":"13_CR56","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1073\/pnas.83.6.1817","volume":"83","author":"OT Mueller","year":"1986","unstructured":"Mueller OT, Henry WM, Haley LL, Byers MG, Eddy RL, Shows TB (1986) Sialidosis and Galactosialidosis: chromosomal assignment of two genes associated with neuraminidase-deficiency disorders. Proc Natl Acad Sci USA 83:1817\u20131821. https:\/\/doi.org\/10.1073\/pnas.83.6.1817","journal-title":"Proc Natl Acad Sci USA"},{"key":"13_CR57","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s100380070034","volume":"45","author":"Y Naganawa","year":"2000","unstructured":"Naganawa Y et al (2000) Molecular and structural of Japanese patients with Sialidosis type 1. J Hum Genet 45:241\u2013249. https:\/\/doi.org\/10.1007\/s100380070034","journal-title":"J Hum Genet"},{"key":"13_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41439-019-0054-x","volume":"6","author":"H Nakajima","year":"2019","unstructured":"Nakajima H et al (2019) A new heterozygous compound mutation in the CTSA gene in Galactosialidosis. Hum Genome Var 6:1\u20135. https:\/\/doi.org\/10.1038\/s41439-019-0054-x","journal-title":"Hum Genome Var"},{"key":"13_CR59","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ymgme.2012.07.013","volume":"107","author":"EM O\u2019Learya","year":"2012","unstructured":"O\u2019Learya EM, Igdoura AI (2012) The therapeutic potential of pharmacological chaperones and proteosomal inhibitors, Celastrol and MG132 in the treatment of sialidosis. Mol Genet Metab 107:173\u2013185. https:\/\/doi.org\/10.1016\/j.ymgme.2012.07.013","journal-title":"Mol Genet Metab"},{"key":"13_CR60","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/glycob\/cwj069","volume":"16","author":"Y Oheda","year":"2006","unstructured":"Oheda Y et al (2006) Elimination of abnormal Sialylglycoproteins in fibroblasts with Sialidosis and Galactosialidosis by normal gene transfer and enzyme replacement. Glycobiol 16:271\u2013280. https:\/\/doi.org\/10.1093\/glycob\/cwj069","journal-title":"Glycobiol"},{"key":"13_CR61","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/BF00295374","volume":"170","author":"T Oohira","year":"1985","unstructured":"Oohira T, Nagata N, Akaboshi I, Matsuda I, Naito S (1985) The infantile form of Sialidosis type II associated with congenital adrenal hyperplasia: possible linkage between HLA and the neuraminidase deficiency gene. Hum Genet 170:341\u2013343. https:\/\/doi.org\/10.1007\/BF00295374","journal-title":"Hum Genet"},{"key":"13_CR62","doi-asserted-by":"publisher","first-page":"222","DOI":"10.14740\/wjon1509","volume":"13","author":"Q Peng","year":"2022","unstructured":"Peng Q, Gao L, Cheng HB, Wang JS, Wang J (2022) Sialidase NEU1 May Serve as a Potential Biomarker of Proliferation, Migration and Prognosis in Melanoma. World J Oncol 13:222\u2013234. https:\/\/doi.org\/10.14740\/wjon1509","journal-title":"World J Oncol"},{"key":"13_CR63","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1007\/s40265-014-0296-3","volume":"74","author":"RM Poole","year":"2014","unstructured":"Poole RM (2014) Eliglustat: first global approval. Drugs 74:1829\u20131836. https:\/\/doi.org\/10.1007\/s40265-014-0296-3","journal-title":"Drugs"},{"key":"13_CR64","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/ng0397-316","volume":"15","author":"AV Pshezhetsky","year":"1997","unstructured":"Pshezhetsky AV (1997) Cloning, expression and chromosomal mapping of human lysosomal sialidase and characterization of mutations in sialidosis. Nat Genet 15:316\u2013320. https:\/\/doi.org\/10.1038\/ng0397-316","journal-title":"Nat Genet"},{"key":"13_CR65","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/ana.410030309","volume":"3","author":"I Rapin","year":"1978","unstructured":"Rapin I, Goldfischer S, Katzman R, Engel J Jr, O\u2019Brien JS (1978) The cherry-red spot\u2013myoclonus syndrome. Ann Neurol 3:234\u2013242. https:\/\/doi.org\/10.1002\/ana.410030309","journal-title":"Ann Neurol"},{"key":"13_CR66","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/j.1365-2958.1993.tb01221.x","volume":"9","author":"P Roggentin","year":"1993","unstructured":"Roggentin P, Schauer R, Hoyer LL, Vimr ER (1993) The sialidase superfamily and its spread by horizontal gene transfer. Mol Microbiol 9:915\u2013921. https:\/\/doi.org\/10.1111\/j.1365-2958.1993.tb01221.x","journal-title":"Mol Microbiol"},{"key":"13_CR67","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/hmg\/7.2.313","volume":"7","author":"RJ Rottier","year":"1998","unstructured":"Rottier RJ, Bonten E, d'Azzo A (1998) A point mutation in the neu-1 locus causes the neuraminidase defect in the SM\/J mouse. Hum Mol Genet 7:313\u2013321. https:\/\/doi.org\/10.1093\/hmg\/7.2.313","journal-title":"Hum Mol Genet"},{"key":"13_CR68","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/0009-8981(82)90257-1","volume":"125","author":"H Sakuraba","year":"1982","unstructured":"Sakuraba H, Aoyagi T, Suzuki Y (1982) Galactosialidosis (beta-galactosidase-neuraminidase deficiency): a possible role of serine-thiol proteases in the degradation of beta-galactosidase molecules. Clin Chim Acta 125:275\u2013283. https:\/\/doi.org\/10.1016\/0009-8981(82)90257-1","journal-title":"Clin Chim Acta"},{"key":"13_CR69","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","volume":"378","author":"A Schulz","year":"2018","unstructured":"Schulz A et al (2018) CLN2 Study Group. Study of intraven-tricular cerliponase alfa for CLN2 disease. N Engl J Med 378:1898\u20131907. https:\/\/doi.org\/10.1056\/NEJMoa1712649","journal-title":"N Engl J Med"},{"key":"13_CR70","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.omtm.2021.02.018","volume":"21","author":"JH Seo","year":"2021","unstructured":"Seo JH, Kosuga M, Hamazaki T, Shintaku H, Okuyama T (2021) Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II. Mol Ther Methods Clin Dev 21:67\u201375. https:\/\/doi.org\/10.1016\/j.omtm.2021.02.018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"13_CR72","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1172\/JCI116472","volume":"91","author":"M Shimmoto","year":"1993","unstructured":"Shimmoto M, Fukuhara Y, Itoh K, Oshima A, Sakuraba H, Suzuki Y (1993) Protective protein gene mutations in Galactosialidosis. J Clin Invest 91:2393\u20132398. https:\/\/doi.org\/10.1172\/JCI116472","journal-title":"J Clin Invest"},{"key":"13_CR73","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/jimd.12010","volume":"42","author":"T Sl\u00e1ma","year":"2019","unstructured":"Sl\u00e1ma T, Garbade SF, K\u00f6lker S, Hoffmann GF, Ries M (2019) Quantitative natural history characterization in a cohort of 142 published cases of patients with galactosialidosis\u2014a cross-sectional study. J Inherit Metab Dis 42:295\u2013302. https:\/\/doi.org\/10.1002\/jimd.12010","journal-title":"J Inherit Metab Dis"},{"key":"13_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106320","volume":"9","author":"V Smutova","year":"2014","unstructured":"Smutova V et al (2014) Structural basis for substrate specificity of mammalian neuraminidases. PLoS One 9:e106320. https:\/\/doi.org\/10.1371\/journal.pone.0106320","journal-title":"PLoS One"},{"key":"13_CR75","first-page":"271","volume":"4","author":"T Takano","year":"1991","unstructured":"Takano T, Shimmoto M, Fukuhara Y, Itoh K, Kase R, Takiyama N, Kobayashi T, Oshima A, Sakuraba H, Suzuki Y (1991) Galactosialidosis: clinical and molecular analysis of 19 Japanese patients. Brain Dysfunct 4:271\u2013280","journal-title":"Brain Dysfunct"},{"key":"13_CR76","first-page":"3507","volume-title":"The metabolic and molecular bases of inherited disease","author":"GH Thomas","year":"2001","unstructured":"Thomas GH (2001) Disorders of glycoprotein degradation and structure: \u03b1-mannosidosis, \u03b2-mannosidosis, fucosidosis, and sialidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, vol 3, 8th edn. McGraw-Hill, pp 3507\u20133534","edition":"8"},{"key":"13_CR77","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1021\/acsabm.1c01043","volume":"5","author":"J Tsukimoto","year":"2022","unstructured":"Tsukimoto J, Takeuchi Y, Horii Y, Iniwa T, Fukushi Y, Nishioka SI, Itoh K (2022) In cellulo crystallization of human neuraminidase 1 and biological roles of N-Glycans. ACS Appl Bio Mater 5:205\u2013213. https:\/\/doi.org\/10.1021\/acsabm.1c01043","journal-title":"ACS Appl Bio Mater"},{"key":"13_CR78","doi-asserted-by":"publisher","first-page":"eaav3270","DOI":"10.1126\/sciadv.aav3270","volume":"5","author":"D van de Vlekkert","year":"2019","unstructured":"van de Vlekkert D et al (2019) Excessive exosome release is the pathogenic pathway linking a lysosomal deficiency to generalized fibrosis. Sci Adv 5:eaav3270. https:\/\/doi.org\/10.1126\/sciadv.aav3270","journal-title":"Sci Adv"},{"key":"13_CR79","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1016\/j.ymthe.2024.05.029","volume":"23","author":"D van de Vlekkert","year":"2024","unstructured":"van de Vlekkert D et al (2024) AAV-mediated gene therapy for sialidosis. Mol Ther 23:2094\u20132112. https:\/\/doi.org\/10.1016\/j.ymthe.2024.05.029","journal-title":"Mol Ther"},{"key":"13_CR80","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1093\/emboj\/17.6.1588","volume":"17","author":"A van Der Spoel","year":"1998","unstructured":"van Der Spoel A, Bonten E, d\u2019Azzo A (1998) Transport of human lysosomal neuraminidase to mature lysosomes requires protective protein\/Cathepsin A. EMBO J 17:1588\u20131597. https:\/\/doi.org\/10.1093\/emboj\/17.6.1588","journal-title":"EMBO J"},{"key":"13_CR81","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1006\/bbrc.1999.0973","volume":"261","author":"T Wada","year":"1999","unstructured":"Wada T, Yoshikawa Y, Tokuyama S, Kuwabara M, Akita H, Miyagi T (1999) Cloning, expression, and chromosomal mapping of a human ganglioside sialidase. Biochem Biophys Res Commun 261:21\u201327. https:\/\/doi.org\/10.1006\/bbrc.1999.0973","journal-title":"Biochem Biophys Res Commun"},{"key":"13_CR82","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ymgme.2005.03.007","volume":"85","author":"D Wang","year":"2005","unstructured":"Wang D, Bonten EJ, Yogalingam G, Mann L, d'Azzo A (2005) Short-term, high dose enzyme replacement therapy in sialidosis mice. Mol Genet Metab 85:181\u2013189. https:\/\/doi.org\/10.1016\/j.ymgme.2005.03.007","journal-title":"Mol Genet Metab"},{"key":"13_CR83","doi-asserted-by":"publisher","first-page":"14689","DOI":"10.1074\/jbc.RA118.004589","volume":"293","author":"EJ White","year":"2018","unstructured":"White EJ et al (2018) Sialidase down-regulation reduces non-HDL cholesterol, inhibits leukocyte transmigration, and attenuates atherosclerosis in ApoE knockout mice. J Biol Chem 293:14689\u201314706. https:\/\/doi.org\/10.1074\/jbc.RA118.004589","journal-title":"J Biol Chem"},{"key":"13_CR84","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.bbadis.2009.10.008","volume":"1802","author":"X Wu","year":"2010","unstructured":"Wu X et al (2010) Vacuolization and alterations of lysosomal membrane proteins in cochlear marginal cells contribute to hearing loss in neuraminidase 1-deficient mice. Biochim Biophys Acta 1802:259\u2013268. https:\/\/doi.org\/10.1016\/j.bbadis.2009.10.008","journal-title":"Biochim Biophys Acta"},{"key":"13_CR86","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.devcel.2008.05.005","volume":"15","author":"G Yogalingam","year":"2008","unstructured":"Yogalingam G, Bonten EJ, van de Vlekkert D, Hu H, Moshiach S, Connell SA, d'Azzo A (2008) Neuraminidase 1 is a negative regulator of lysosomal exocytosi. Dev Cell 15:74\u201386. https:\/\/doi.org\/10.1016\/j.devcel.2008.05.005","journal-title":"Dev Cell"},{"key":"13_CR87","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.bbadis.2010.04.002","volume":"1802","author":"E Zanoteli","year":"2010","unstructured":"Zanoteli E (2010) Muscle degeneration in neuraminidase 1-deficient mice results from infiltration of the muscle fibers by expanded connective tissue. Biochim Biophys Acta 1802:659\u2013672. https:\/\/doi.org\/10.1016\/j.bbadis.2010.04.002","journal-title":"Biochim Biophys Acta"},{"key":"13_CR88","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1101\/gad.9.21.2623","volume":"9","author":"XY Zhou","year":"1995","unstructured":"Zhou XY et al (1995) Mouse model for the lysosomal disorder galactosialidosis and correction of the phenotype with overexpressing erythroid precursor cells. Genes Dev 9:2623\u20132634. https:\/\/doi.org\/10.1101\/gad.9.21.2623","journal-title":"Genes Dev"},{"key":"13_CR89","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-019-0500-x","volume":"18","author":"X Zhou","year":"2020","unstructured":"Zhou X et al (2020) Sialidase NEU1 suppresses progression of human bladder cancer cells by inhibiting fibronectin-integrin alpha5beta1 interaction and Akt signaling pathway. Cell Commun Signal 18:44. https:\/\/doi.org\/10.1186\/s12964-019-0500-x","journal-title":"Cell Commun Signal"}],"container-title":["Advances in Experimental Medicine and Biology","The Molecular Immunology of Complex Carbohydrates - 4"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-032-04153-1_13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T23:30:16Z","timestamp":1774999816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-032-04153-1_13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9783032041524","9783032041531"],"references-count":87,"URL":"https:\/\/doi.org\/10.1007\/978-3-032-04153-1_13","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"1 April 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"Competing interests\n                      None declared conflict of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}]}}